Axonics, Inc. has filed a premarket approval (PMA) supplement with the FDA for its newly developed, long-lived, non-rechargeable sacral neuromodulation (SNM) implantable neurostimulator (INS). The company has designed its new non-rechargeable SNM system to replicate key features of its currently marketed, FDA-approved rechargeable SNM system, which provides patients with clinically significant, durable symptom relief and high levels of satisfaction. Once approved, the Axonics non-rechargeable system will be the first fully recharge-free SNM system and have the following attributes: INS type and longevity: primary cell battery with an expected life of at least 10 years with standard stimulation parameters; INS size: 11 cubic centimeters; Stimulation: constant current; MRI compatibility: full-body with 1.5T and 3.0T scanners; Patient remote control: intuitive, recharge-free key fob featuring SmartMRI™technology; Programming: utilizes proprietary algorithm to recommend the best program.